MedTrace Logo

Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer

NCT00265200 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2018-03-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate a new blood test as a way to follow the effect of Zometa in treating bone metastases due to lung cancer.

Conditions

  • Carcinoma, Non-Small Cell Lung
  • Carcinoma, Small Cell Lung
  • Metastases

Interventions

DRUG

zoledronic acid

3.0-4.0 mg by IV (in the vein), once a month for 6 months

Sponsors & Collaborators

  • James Graham Brown Cancer Center

    collaborator OTHER

  • Novartis Pharmaceuticals

    collaborator INDUSTRY

  • University of Louisville

    lead OTHER

Principal Investigators

  • Goetz H Kloecker, MD, MSPH · James Graham Brown Cancer Center/ University of Louisville

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28
Primary Completion
2009-08-31
Completion
2010-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00265200 on ClinicalTrials.gov